Meropenem
Composition
InpenTM 500 mg IV injection: Each vial contains Meropenem USP 500 mg.
InpenTM 1 g IV injection: Each vial contains Meropenem USP 1 g.
Indications
InpenTM is indicated for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the
identification of the causative organisms: Lower Respiratory Tract Infections, Urinary Tract Infections, including complicated infections, Intra-abdominal Infections, Gynaecological infections, including
postpartum infections, Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment, including initial monotherapy, for presumed bacterial
infections in host-compromised, neutropenic patient.
Because of its broad spectrum or bactericidal activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. InpenTM is effective for the treatment of
polymicrobial infections.
Dosage and Administration
ADULTS:
Usual dose: 500 mg to 1 g by intravenous administration every 8 hours depending on type end severity of Infection.
Exceptions: 1. Febrile episodes to neutropenic patients - the dose should be I g every 8 hours. 2. Meningitis- the dose should be 2 g every 8 hours.
As with other antibiotic, caution may be required in using Meropenem as monotherapy in critically iII patients with known or suspected Pseudomonas aeruginosa lower
respiratory tract erections. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infections.
InpenTM should be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 to 30 minutes (see Method of
Administration).
ELDERLY
No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
CHILDREN
For infants and children over 3 months and up to 12 years of age, the recommended intravenous dose is 10 to 40 mg/kg every 8 hours depending on type and severity of
infection, the known or suspected susceptibility of the pathogen(s) and the condition of the patient. In children over 50 kg weight, adult dosage should be used.
Methenamine Hippurate
Composition
Methebac Tablet: Each tablet contains Methenamine
Hippurate USP 1 g.
Indications
Methebac is indicated for prophylactic or suppressive
treatment of frequently recurring urinary tract infections
when long-term therapy is considered necessary. This
drug should only be used after eradication of the
infection by other appropriate antimicrobial agents.
Dosage & Administration
1 tablet (1.0 g) twice daily (morning and night) for adults
and paediatric patients over 12 years of age. 1/2 to 1
tablet (0.5 to 1.0 g) twice daily (morning and night) for
paediatric patients 6 to 12 years of age. Since the
antibacterial activity of Methebac is greater in acid urine,
restriction of alkalinizing foods and medications is
desirable or as directed by the physician.
Mirogabalin
Composition
Neumir 2.5 Tablet : Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 2.5 mg
Neumir 5 Tablet : Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 5 mg
Neumir 10 Tablet : Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 10 mg
Indications
Peripheral neuropathic pain including:
• Diabetic peripheral neuropathy
• Post-herpetic neuralgia
• Spinal pain
Dosage and Administration
Normally, the initial dose for adults is 5 mg of Mirogabalin given orally twice daily and then the dose may be gradually increased by 5 mg at an interval of at least a week to 15 mg, given orally twice daily. A dose may be adjusted appropriately between 10 mg and 15 mg depending on ages and symptoms, taken twice daily or as directed by the physician. Mirogabalin can be taken with or without food. If the patient misses a dose, he/she must take the missed dose as soon as possible. If it is almost time for the next dose, the patient should skip the missed dose and continue his/her regular dosing schedule.
Mirogabalin dosage adjustment based on renal function: No dose adjustment is recommended in mild renal impairment. Dose to be reduced to 50% in moderate renally impaired patients. A dose reduction of up to 75% required in patients with severe renal impairment and End-Stage Renal Disease.
Degree of Renal Dysfunction (Clcr: mL/min)
Mild Moderate Severe (including hemodialysis patients)
(90 > Clcr ≥ 60) (60 > Clcr ≥ 30) (30 > Clcr)
Daily dose 10 - 30 mg 5 - 15 mg 2.5 - 7.5 mg
Initial dose 5 mg twice daily 2.5 mg twice daily 2.5 mg once daily
Effective dose-
Minimum dose 10 mg twice daily 5 mg twice daily 5 mg once daily
Recommended-
dose 15 mg twice daily 7.5 mg twice daily 7.5 mg once daily
Multivitamin+ Codliver Oil
Description:
RevamTM kidssyrup is a balanced combination of eight essential vitamins and cod liver oil which adequately replenish the deficiency of vitamin and supports proper growth and healthy development of children.
RevamTM kids syrup contains cod liver oil which is the nature's most abundant sources of vitamin A and D. It is also particularly rich source of rare eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which make up the important omega-3 essential fatty acids. They help
maintain a healthy blood circulation by lowering serum triglyceride levels and reducing the tendency for blood to clot. Besides keeping the body fit and healthy, it also builds resistance for infections, such as cough, cold, chest and bronchial troubles
Indication:
RevamTM Kids syrup is indicated for the treatment and prevention of vitamin deficiencies with restricted diets, improper food intake and decreased absorption. It is also indicated in children with increased
requirement of vitamins due to acute and chronic disease, vitamin lacking symptoms for growing child, lack of appetite, including patients under rehabilitating period.
Dosage and Administration:
Infants (1-12 months): 1/2 tea spoon full (2.5 ml) daily
Child (1-4 years): 1 tea spoon full (5 ml) daily
Child (Above 4 years): 11/2 tea spoon full (7.5 ml) daily
Adult: 2 tea spoon full (10 ml) daily
Momeasone
Composition:
Momespray™: Each spray contains Mometasone Furoate BP 50 meg.
Indication:
Momespray™ is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It
is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. It is also indicated for the treatment of
nasal polyps in patients 18 years and older.
Dose & Administration:
Administer Mometasone Nasal Spray by the intranasal route only.
Allergic Rhinitis
Adults and Children 12 Years of Age and Older: For prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal
symptoms of perennial allergic rhinitis use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg). In patients
with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis use Momespray™ 50 meg (200 meg/day) 2 to 4 weeks prior
to the anticipated start of the pollen season.
Children (2 to 11 years of age) For treatment of the nasal symptoms of seasonal and perennial allergic rhinitis use one spray (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg).
Nasal Polyps
Adults 18 years of Age and Older: For nasal polyps use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400
meg). A dose of two sprays (50 meg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 meg) is also effective in some patients.
Metformine
Composition:
NVmet™ 500 Tablet: Each film coated tablet contains Metformin Hydrochloride BP 500 mg.
NVmet™ 850 Tablet: Each film coated tablet contains Metformin Hydrochloride BP 850 mg.
NVmet™ 500 SR Tablet: Each sustained release tablet contains Metformin Hydrochloride BP 500 mg.
Indication:
NVmet™, as monotherapy, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. NVmet™ is also indicated for use in combination with other agents, that do not result in adequate glycemic control.
Dose and administration:
Diabetes mellitus: Adult and child over 10 years initially 500 mg with breakfast for at least 1 week, then 500 mg with breakfast and evening meal for at least 1 week, then 500 mg with breakfast, lunch and evening meal; usual max. 2 g daily in divided doses.
Polycystic ovary syndrome: initially 500 mg with breakfast for 1 week, then 500 mg with breakfast and evening meal for 1 week, then 1.5-1.7 g daily in 2-3 divided doses or as directed by the physician.
Moxifloxacin + Dexamethasone
Composition:
Cinagen™-D Sterile Eye Drops: Each ml contains Moxifloxacin
Hydrochloride BP equivalent to Moxifloxacin 5 mg and Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 1 mg.
Preservative: Sodium Perborate BP 0.001%.
Indications:
Cinagen™-D Sterile Eye Drops is indicated for the treatment of eye infections caused by susceptible microorganisms and prevention of inflammation and bacterial infection occurred after ocular surgery.
Dosage and administration:
In the prevention of infection and postoperative ocular inflammation, instill 1 drop 4 times per day. Frequency should be decreased gradually with improvement of clinical signs or as directed by the physician.
Moxifloxacin
Composition
Cinagen™ Sterile Eye Drops: Each ml contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 5 mg.
Cinagen™ XG Sterile Eye Drops: Each ml contains Moxifloxacin
Hydrochloride BP equivalent to Moxifloxacin 5 mg (enriched with Xanthan Gum BP 0.4%).
Indications
Cinagen™ is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of following organisms:
Aerobic gram-positive microorganism: Corynebacterium species, Micrococus luteus, Staphylococcus aureus, Staphylococus epidermis, Staphylococus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group Aerobic Gram-negative microorganisms: Acinetobacter iwoffi, Haemophilusinfluenzae, Haemophilus parainfluenzae.
Dosage and administration
Cinagen™ Sterile Eye Drops: One drop in the affected eyes 3 times per day for 7 days or as directed by the physician.
Cinagen™ XG Sterile Eye Drops: One drop in the affected eyes 2 times per day for 7 days or as directed by the physician.
Montelukast
Composition:
Arokast™10: Each film coated tablet contains Montelukast Sodium USP equivalent to Montelukast 10 mg.
Arokast™ 4 FT: Each film coated tablet contains Montelukast Sodium USP equivalent to Montelukast 4 mg.
Arokast™ 5 FT: Each film coated tablet contains Montelukast Sodium USP equivalent to Montelukast 5 mg.
Indication:
Montelukast is indicated for the prophylaxis of asthma and management of chronic asthma; symptomatic relief of seasonal allergic rhinitis in patients with asthma.
Dosage & Administration:
Prophylaxis of asthma:
Adult and Child over 15 years: 10 mg once daily in the evening.
Child 6-15 years: 5 mg once daily in the evening.
Child 6 months-6 years: 4 mg once daily in the evening.
Seasonal allergic rhinitis:
Adult and Child over 15 years, 10 mg once daily in the evening. The safety and efficacy of Montelukast was demonstrated in clinical trials where it was administered in the evening without
regard to the time of food ingestion.
